Analytical Data
-
Gene name
snrnp35
- Application
-
Alternative Names
snrnp35;HM1;U1SNRNPBP;;U11/U12 small nuclear ribonucleoProtein 35 kDa Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q4KMD3
-
Expression Region
1-208aa
-
AA Sequence
MEWSPVAKVYDPLKAGSIDGTDVEPHDAGVWRAMLARYKPNRGVCGDPDLTLFVARLNPQTTEEKLRDVFSKFGDIRRLRLVRDVVTGFSKRYAFIEYKEERSLKRAWRDANKLILDQYELLVDVEQERTLPGWRPRRLGGGQGGQKESGQLRFGGRDRPFRKPINLSTRRPAEPRGRETERERDRRDYRDRRHERTHTEDRTHRHTY
-
Molecular Weight
28.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SNRNP35, a component of the spliceosomal small nuclear ribonucleoproteins (snRNPs), plays a crucial role in the pre-mRNA splicing process, a fundamental step in gene expression. It is part of the U5 snRNP, which is essential for the correct assembly and function of the spliceosome, the molecular machinery responsible for removing introns from precursor mRNA transcripts. Recent studies have shown that dysfunctional SNRNP35 can lead to aberrant splicing events, which may contribute to various diseases, including certain cancers and neurodegenerative disorders. Research into SNRNP35 and its interactions within the spliceosome is vital for understanding the intricate mechanisms of RNA processing and how their dysregulation can impact cellular function and lead to disease. Additionally, exploring the recombinant expression of SNRNP35 can provide insights into its structural properties and functional dynamics, allowing for the identification of potential therapeutic targets. This emphasizes the importance of SNRNP35 in both basic biology and clinical research, highlighting a growing interest in its potential as a biomarker and target for therapeutic intervention in splicing-related disorders.











